Orasis Pharmaceuticals is focused on addressing presbyopia, a common age-related condition that affects the ability to focus on near objects, impacting millions of individuals globally. The company is set to launch QLOSI™, a novel treatment aimed at redefining the possibilities for eye care providers and their presbyopic patients. This innovative solution is designed to enhance near visual acuity, thereby improving the daily lives of those affected by this condition. By positioning itself as an agile partner to the eye care community, Orasis Pharmaceuticals aims to disrupt conventional approaches to vision care and provide effective solutions for presbyopia.

The company recognizes the significant prevalence of presbyopia, which affects over 128 million people in the U.S. and approximately 1.8 billion worldwide, particularly as individuals age. The natural aging process leads to the stiffening of the crystalline lens in the eye, resulting in blurred vision for tasks that require close focus, such as reading or using digital devices. Orasis Pharmaceuticals is committed to advancing eye care through its innovative technologies, with a focus on improving the quality of life for those experiencing the challenges associated with presbyopia.

United States

Orasis is reshaping vision possibilities. As agile partners to the eye care community, we see every day as an opportunity to disrupt conventional thinking in pursuit of vision without limitations. That is why we reimagined existing and well-studied molecules to create a unique prescription eye drop for presbyopia, QLOSI™.

Orasis Pharmaceuticals

Company Details